Silo Pharma, Inc. financial data

Symbol
SILO on Nasdaq
Location
677 N. Washington Blvd, Sarasota, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 554 % -35.2%
Debt-to-equity 37.5 % +37.8%
Return On Assets -68.6 % -54.8%
Operating Margin -7.16K % -35.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.4M shares +110%
Common Stock, Shares, Outstanding 8.65M shares +133%
Entity Public Float 3.43M USD -42.5%
Common Stock, Value, Issued 865 USD +112%
Weighted Average Number of Shares Outstanding, Basic 6.28M shares +106%
Weighted Average Number of Shares Outstanding, Diluted 6.28M shares +106%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 72.1K USD 0%
Cost of Revenue 5.84K USD 0%
Research and Development Expense 2.97M USD +143%
Operating Income (Loss) -5.17M USD -35.3%
Nonoperating Income (Expense) 271K USD -27.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.9M USD -42.1%
Income Tax Expense (Benefit) 906K USD +50.3%
Net Income (Loss) Attributable to Parent -4.9M USD -39.3%
Earnings Per Share, Basic -1 USD/shares +13.6%
Earnings Per Share, Diluted -1 USD/shares +13.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.33M USD -3.83%
Assets, Current 6.37M USD -17.5%
Intangible Assets, Net (Excluding Goodwill) 223K USD -9.76%
Assets 6.65M USD -17.2%
Accounts Payable, Current 144K USD
Contract with Customer, Liability, Current 72.1K USD 0%
Liabilities, Current 1.05M USD -20.6%
Contract with Customer, Liability, Noncurrent 686K USD -9.52%
Liabilities 1.74M USD -16.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 9.56K USD +19.2%
Retained Earnings (Accumulated Deficit) -17.5M USD -38.8%
Stockholders' Equity Attributable to Parent 4.92M USD -17.5%
Liabilities and Equity 6.65M USD -17.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.64M USD -95.7%
Net Cash Provided by (Used in) Financing Activities -115K USD
Net Cash Provided by (Used in) Investing Activities 871K USD +793%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 8.65M shares +112%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.33M USD -3.83%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.07K USD +10.5%
Deferred Tax Assets, Valuation Allowance 3.71M USD +46.2%
Deferred Tax Assets, Gross 3.71M USD +46.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.89M USD -39.7%
Lessee, Operating Lease, Liability, to be Paid 1.88M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.88M USD
Deferred Tax Assets, Operating Loss Carryforwards 2.96M USD +25.6%
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 22.4M USD +16.7%
Amortization of Intangible Assets 3.09K USD
Deferred Tax Assets, Net of Valuation Allowance 2.54M USD +63.7%
Interest Expense 5.08K USD +13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%